SHC · Sotera Health Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.16B | $1.10B | $1.05B | $1.00B | $818.16M |
| Cost of Revenue | $518.08M | $498.15M | $472.13M | $446.68M | $374.59M |
| Gross Profit | $645.53M | $602.29M | $577.16M | $557.00M | $443.57M |
| R&D | - | - | - | - | - |
| SG&A | $252.76M | $242.63M | $236.67M | $245.71M | $178.53M |
| Total Operating Expenses | - | $304.67M | $300.47M | $308.65M | $237.55M |
| D&A | $94.90M | $84.30M | $76.60M | $64.30M | $63.30M |
| Operating Income | $147.51M | $297.63M | $276.69M | $248.35M | $206.02M |
| Interest Expense | - | - | - | - | - |
| Income Tax | $69.56M | $69.48M | $54.65M | ($9.54M) | ($1.37M) |
| Net Income | $77.95M | $44.40M | $51.38M | ($233.57M) | ($38.62M) |
| EPS - Basic | $0.27 | $0.16 | $0.18 | ($0.83) | ($0.16) |
| EPS - Diluted | $0.27 | $0.16 | $0.18 | ($0.83) | ($0.16) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $344.62M | $277.24M | $296.41M | $395.21M | $106.92M |
| Accounts Receivable | $139.33M | $140.33M | $147.70M | $118.48M | $108.18M |
| Inventory | $54.38M | $49.16M | $48.32M | $37.15M | $54.29M |
| Accounts Payable | $77.96M | $55.10M | $71.04M | $74.14M | $72.87M |
| Current Assets | $613.41M | $526.04M | $557.24M | $645.01M | $345.96M |
| Total Assets | $3.26B | $3.07B | $3.13B | $3.12B | $2.79B |
| Current Liabilities | $249.58M | $191.00M | $230.65M | $791.57M | $161.16M |
| Long-term Debt | $2.13B | $2.21B | $2.22B | $1.75B | $1.74B |
| Total Liabilities | $2.66B | $2.67B | $2.69B | $2.77B | $2.20B |
| Stockholders' Equity | $606.03M | $404.91M | $443.73M | $350.24M | $586.10M |
| Retained Earnings | ($532.09M) | ($610.04M) | ($654.44M) | ($705.82M) | ($472.25M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $287.19M | $224.16M | ($147.73M) | $277.96M | $120.58M |
| Investing Cash Flow | ($135.14M) | ($179.00M) | ($214.91M) | ($181.90M) | ($158.69M) |
| Financing Cash Flow | ($100.53M) | ($50.56M) | $265.96M | $197.76M | $73.43M |
| CapEx | $138.02M | $179.07M | $214.97M | $182.38M | $53.51M |
| Free Cash Flow | $149.18M | $45.09M | ($362.71M) | $95.58M | $67.08M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 55.5% | 54.7% | 55.0% | 55.5% | 54.2% |
| Operating margin | 12.7% | 27.0% | 26.4% | 24.7% | 25.2% |
| EBITDA margin | 20.8% | 34.7% | 33.7% | 31.2% | 32.9% |
| Net margin | 6.7% | 4.0% | 4.9% | -23.3% | -4.7% |
| Free cash flow margin | 12.8% | 4.1% | -34.6% | 9.5% | 8.2% |
| FCF / Net income | 1.91 | 1.02 | -7.06 | -0.41 | -1.74 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 21.7% | 22.0% | 22.6% | 24.5% | 21.8% |
| Effective tax rate | 47.2% | 61.0% | 51.5% | - | - |
| Return on assets | 2.4% | 1.4% | 1.6% | -7.5% | -1.4% |
| Return on equity | 12.9% | 11.0% | 11.6% | -66.7% | -6.6% |
| Return on invested capital | 2.9% | 5.7% | 5.2% | 9.4% | 7.0% |
| Liquidity | |||||
| Current ratio | 2.46 | 2.75 | 2.42 | 0.81 | 2.15 |
| Quick ratio | 2.24 | 2.50 | 2.21 | 0.77 | 1.81 |
| Cash ratio | 1.38 | 1.45 | 1.29 | 0.50 | 0.66 |
| Leverage | |||||
| Debt / Equity | 3.51 | 5.45 | 5.01 | 4.99 | 2.97 |
| Debt / Assets | 0.65 | 0.72 | 0.71 | 0.56 | 0.63 |
| Debt / EBITDA | 8.77 | 5.78 | 6.29 | 5.59 | 6.47 |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 5.38 | 7.59 | 7.05 | 8.90 | 4.76 |
| Liabilities / Assets | 0.81 | 0.87 | 0.86 | 0.89 | 0.79 |
| Efficiency | |||||
| Asset turnover | 0.36 | 0.36 | 0.34 | 0.32 | 0.29 |
| Inventory turnover | 9.53 | 10.13 | 9.77 | 12.03 | 6.90 |
| Days sales outstanding | 44d | 47d | 51d | 43d | 48d |
| Days inventory outstanding | 38d | 36d | 37d | 30d | 53d |
| Days payable outstanding | 55d | 40d | 55d | 61d | 71d |
| Cash conversion cycle | 27d | 42d | 34d | 13d | 30d |
| Valuation | |||||
| P / E | 65.3x | 85.5x | 93.6x | - | - |
| P / B | 8.3x | 9.6x | 10.8x | 6.7x | 9.6x |
| P / S | 4.3x | 3.5x | 4.5x | 2.3x | 6.8x |
| EV / EBITDA | 28.2x | 15.3x | 19.0x | 11.8x | 26.9x |
| Growth | |||||
| Revenue growth (YoY) | 5.7% | 4.9% | 4.5% | 22.7% | - |
| Revenue CAGR (3y) | 5.1% | 10.4% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 7.2% | 4.4% | 3.6% | 25.6% | - |
| Operating income growth (YoY) | -50.4% | 7.6% | 11.4% | 20.5% | - |
| Net income growth (YoY) | 75.6% | -13.6% | - | -504.8% | - |
| EPS growth (YoY) | 68.8% | -11.1% | - | -418.7% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 230.8% | - | - | 42.5% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 49.7% | -8.7% | 26.7% | -40.2% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.16B totalSterigenics$755.78M · 65.2%
Nelson Labs$220.22M · 19.0%
Nordion$182.82M · 15.8%
Product / service
$1.16B totalService$995.76M · 85.6%
Product$167.86M · 14.4%
Geographic
$1.16B totalUS$629.54M · 54.1%
Europe$232.18M · 20.0%
CA$221.95M · 19.1%
Other Geographical Areas$79.95M · 6.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.53
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing Sotera Health Co against the 5 most active filers in the same SIC group.